H.C. Wainwright analyst Edward White maintained a Buy rating on Syndax Pharmaceuticals Inc (SNDX) today and set a price target of $16. The company’s shares opened today at $4.90, close to its 52-week low of $3.39.
According to TipRanks.com, White is a 5-star analyst with an average return of 10.1% and a 47.2% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Aileron Therapeutics Inc, and Synthetic Biologics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Syndax Pharmaceuticals Inc with a $18.67 average price target.
See today’s analyst top recommended stocks >>
Based on Syndax Pharmaceuticals Inc’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $18.84 million. In comparison, last year the company had a GAAP net loss of $19.4 million.
Based on the recent corporate insider activity of 7 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SNDX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include candidate and entinostat. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.
